Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Sep;18(9):58.
doi: 10.1007/s11936-016-0480-8.

Direct Cardiac Cellular Reprogramming for Cardiac Regeneration

Vivekkumar Patel  1 , Megumi Mathison  1 , Vivek P Singh  1 , Jianchang Yang  1 , Todd K Rosengart  2
Affiliations
Review

Direct Cardiac Cellular Reprogramming for Cardiac Regeneration

Vivekkumar Patel et al. Curr Treat Options Cardiovasc Med. 2016 Sep.

Abstract

Direct cardiac cellular reprogramming of endogenous cardiac fibroblasts directly into induced cardiomyocytes is a highly feasible, promising therapeutic option for patients with advanced heart failure. The most successful cardiac reprogramming strategy will likely be a multimodal approach involving an optimal combination of cardio-differentiating factors, suppression of fibroblast gene expression, and induction of angiogenic factors.

Keywords: Cardiomyocyte; GMT; Gene therapy; Heart failure; Reprogramming; Transdifferentiation.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflicts of interest.

References

    1. Baran DA, Jaiswal A. Management of the ACC/AHA Stage D patient: mechanical circulatory support. Cardiol Clin. 2014;32(1):113–124. viii–ix. - PubMed
    1. Kittleson MM, Kobashigawa JA. Management of the ACC/AHA Stage D patient: cardiac transplantation. Cardiol Clin. 2013;32(1):95–112. viii. - PMC - PubMed

    1. Fisher SA, Zhang H, Doree C, Mathur A, Martin-Rendon E. Stem cell treatment for acute myocardial infarction. Cochrane Database Syst Rev. 2015;9:CD006536. This Cochrane review summarizes the results of 41 randomized controlled trials involving bone-marrow stem cell implantation for patients with ischemic heart disease. The difference in left ventricular ejection fraction between the treated and untreated groups was 2–5%, which was determined to not be clinically relevant.

    1. Nagalingam RS, Safi HA, Czubryt MP. Gaining myocytes or losing fibroblasts: challenges in cardiac fibroblast reprogramming for infarct repair. J Mol Cell Cardiol. 2015:108–114. - PubMed
    1. Sadahiro T, Yamanaka S, Ieda M. Direct cardiac reprogramming: progress and challenges in basic biology and clinical applications. Circ Res. 2015;116(8):1378–1391. - PubMed